Japan vs State of Palestine: Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology
Japan
0.0%
in 2024
State of Palestine
0.0%
in 2024
Japan rank
167th
State of Palestine rank
167th
Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology over time
- Japan
- State of Palestine
How they compare
Japan currently reports 0.0% against 0.0% in State of Palestine, a difference of 0.0%.
Across all 10 years both countries report, State of Palestine has been ahead every year.
Japan ranks 167th and State of Palestine ranks 167th of 246 countries.
Head to head by decade
| Decade | Japan | State of Palestine | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 0.0% | 0.0% | 0.0% | — |
| 2020s | 0.0% | 0.0% | 0.0% | — |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence of hepatitis b surface antigen (hbsag), 2026 methodology, Japan or State of Palestine?
- Japan, at 0.0% against 0.0% in State of Palestine as of 2024.
- What is the difference in prevalence of hepatitis b surface antigen (hbsag), 2026 methodology between Japan and State of Palestine?
- 0.0%, with Japan ahead.
- How many years of comparable data are there for Japan and State of Palestine?
- 10 years are reported by both, from 2015 to 2024.
- How do Japan and State of Palestine rank globally for prevalence of hepatitis b surface antigen (hbsag), 2026 methodology?
- Japan ranks 167th and State of Palestine ranks 167th of 246 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.